Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:0
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [1] DISPARITIES IN THE PREVALENCE AND MANAGEMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Estevez, Angela
    Kaul, Sumedh
    Fleishman, Aaron
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Bellmunt, Joaquim
    Olumi, Aria
    Rayala, Heidi
    Gershman, Boris
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1004 - E1004
  • [2] Management of high-risk non-muscle invasive bladder cancer
    Brausi, M.
    Olaru, V.
    MINERVA UROLOGICA E NEFROLOGICA, 2012, 64 (04) : 255 - 260
  • [3] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Werntz, Ryan P.
    Adamic, Brittany
    Steinberg, Gary D.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2031 - 2040
  • [4] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Ryan P. Werntz
    Brittany Adamic
    Gary D. Steinberg
    World Journal of Urology, 2019, 37 : 2031 - 2040
  • [5] The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer
    Bola, Becky
    Hoskin, Peter J.
    Sangar, Vijay
    Choudhury, Ananya
    CANCERS, 2025, 17 (04)
  • [6] Genomic characterization of high-risk non-muscle invasive bladder cancer
    Meeks, Joshua J.
    Carneiro, Benedito A.
    Pai, Sachin G.
    Oberlin, Daniel T.
    Rademaker, Alfred
    Fedorchak, Kyle
    Balasubramanian, Sohail
    Elvin, Julia
    Beaubier, Nike
    Giles, Francis J.
    ONCOTARGET, 2016, 7 (46) : 75176 - 75184
  • [7] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Bashir Al Hussein Al Awamlh
    Sam S. Chang
    Current Oncology Reports, 2023, 25 : 83 - 91
  • [8] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
  • [9] THE OUTCOME OF PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER IN SWEDEN
    Wang, Eugen
    Larsson, Ulf
    Gardmark, Truls
    Malmstrom, Per-Uno
    JOURNAL OF UROLOGY, 2020, 203 : E1077 - E1077
  • [10] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Zieger, Karsten
    Wiuf, Carsten
    Jensen, Klaus Moller-Ernst
    Orntoft, Torben Falck
    Dyrskjot, Lars
    BMC CANCER, 2009, 9